References
- SEER program. Cancer stat facts: melanoma of the skin. (2017). https://seer.cancer.gov/statfacts/html/melan.html
- American Cancer Society. Cancer facts & figures 2017. (2017). www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2017.html
- Agha A , TarhiniAA. Adjuvant therapy for melanoma. Curr. Oncol. Rep.19(5), 36 (2017).
- Gershenwald JE , ScolyerRA, HessKRet al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J. Clin.67(6), 472–492 (2017).
- Karimkhani C , ReddyBY, DellavalleRP, SundararajanS. Novel therapies for unresectable and metastatic melanoma. BMJ359, j5174 (2017).
- Romano E , ScordoM, DuszaSW, CoitDG, ChapmanPB. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J. Clin. Oncol.28(18), 3042–3047 (2010).
- Eggermont AM , Chiarion-SileniV, GrobJJet al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N. Engl. J. Med.375(19), 1845–1855 (2016).
- US FDA. Highlights of Prescribing Information – TAFINLAR® (dabrafenib). (2017). www.accessdata.fda.gov/drugsatfda_docs/label/2017/202806s006lbl.pdf
- US FDA. Highlights of Prescribing Information – MEKINIST® (trametinib). (2017). www.accessdata.fda.gov/drugsatfda_docs/label/2017/204114s005lbl.pdf
- US FDA. Highlights of prescribing information – OPDIVO (nivolumab). (2017). www.accessdata.fda.gov/drugsatfda_docs/label/2017/125554s041lbl.pdf
- Long GV , HauschildA, SantinamiMet al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N. Engl. J. Med.377(19), 1813–1823 (2017).
- Weber J , MandalaM, Del VecchioMet al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N. Engl. J. Med.377(19), 1824–1835 (2017).
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology – Melanoma Version 2.2018. (2018). www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf
- Clarke CA , McKinleyM, HurleySet al. Continued increase in melanoma incidence across all socioeconomic status groups in California, 1998–2012. J. Invest. Dermatol.137(11), 2282–2290 (2017).
- Erdmann F , Lortet-TieulentJ, SchuzJet al. International trends in the incidence of malignant melanoma 1953–2008 are recent generations at higher or lower risk? Int. J. Cancer 132(2), 385–400 (2013).
- Garnett E , TownsendJ, SteeleB, WatsonM. Characteristics, rates, and trends of melanoma incidence among Hispanics in the USA. Cancer Causes Control27(5), 647–659 (2016).
- Glazer AM , WinkelmannRR, FarbergAS, RigelDS. Analysis of trends in US melanoma incidence and mortality. JAMA Dermatol. doi:10.1001/jamadermatol.2016.4512 (2016) ( Epub ahead of print).
- Olazagasti Lourido JM , MaJE, LohseCM, BrewerJD. Increasing incidence of melanoma in the elderly: an epidemiological study in Olmsted County, Minnesota. Mayo Clin. Proc.91(11), 1555–1562 (2016).
- Shaikh WR , DuszaSW, WeinstockMA, OliveriaSA, GellerAC, HalpernAC. Melanoma thickness and survival trends in the United States, 1989 to 2009. J. Natl Cancer Inst.108(1), (2016).
- SEER program. SEER research data record description cases diagnosed in 1973-2014. (2016). https://seer.cancer.gov/data-software/documentation/seerstat/nov2016/TextData.FileDescription.pdf
- Grob JJ , SchadendorfD, LoriganPet al. Eighth American Joint Committee on Cancer (AJCC) melanoma classification: let us reconsider stage III. Eur. J. Cancer91, 168–170 (2018).
- Swerlick RA , ChenS. The melanoma epidemic. Is increased surveillance the solution or the problem?Arch. Dermatol.132(8), 881–884 (1996).
- Swerlick RA , ChenS. The melanoma epidemic: more apparent than real?Mayo Clin. Proc.72(6), 559–564 (1997).
- Watson M , JohnsonCJ, ChenVWet al. Melanoma surveillance in the United States: overview of methods. J. Am. Acad. Dermatol.65(5 Suppl. 1), S6–S16 (2011).
- Linos E , SwetterSM, CockburnMG, ColditzGA, ClarkeCA. Increasing burden of melanoma in the United States. J. Invest. Dermatol.129(7), 1666–1674 (2009).
- Jemal A , SaraiyaM, PatelPet al. Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992–2006. J. Am. Acad. Dermatol.65(5 Suppl. 1), S17–S25 e11-e13 (2011).
- Chen TT . Milestone survival: a potential intermediate endpoint for immune checkpoint inhibitors. J. Natl Cancer Inst.107(9), (2015).
- Kreamer KM . Immune checkpoint blockade: a new paradigm in treating advanced cancer. J. Adv. Pract. Oncol.5(6), 418–431 (2014).
- Luke JJ , OttPA. PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget6(6), 3479–3492 (2015).
- Mayer JE , FathiR, NorrisDA. Inaccuracies in SEER registry data on melanoma thickness. J. Am. Acad. Dermatol.77(1), e17 (2017).
- Center for Disease Control and Prevention. Life expectancy. (2017). www.cdc.gov/nchs/data/hus/hus16.pdf#015